JPRN-UMIN000006690招募中2 期
Efficacy of NK1 receptor antagonist (aprepitant) in the cancer chemotherapies for hematologic malignancies. - Efficacy of aprepitant in the chemotherapies for hematologic malignancies.
Kagoshima University Hospital, division of Hematology and Immunology0 个研究点目标入组 40 人开始时间: 2011年11月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •patients unable to answer the questions about efficacy of aprepitant
研究者
相似试验
招募中
不适用
Study of NK1-receptor antagonist; aprepitant for prevention of nausea and emesis in patients receiving chemotherapy with irinotecan for gastric cancer.Advanced gastric cancerJPRN-UMIN000011962Gastroenterologic Surgery, Kanazawa University55
已完成
3 期
Four drug anti-emetic studyCTRI/2021/04/032528CI AIIMS250
已完成
不适用
fMRI study on effect of NK1 antagonist (Aprepitant) on cognitive function in normal subjectsSubstance-related disorders, Mood disorders, Anxiety disordersJPRN-UMIN000004381ippon Medical School20
招募中
不适用
Effect of oral neurokinin-1 antagonist, aprepitant for chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving carboplatin/paclitaxel chemotherapy.JPRN-UMIN000005317Department of gynecology, Fukuoka University Hospital60
招募中
不适用
Study of oral neurokinin-1 antagonist, aprepitant for the prevention of nausea and vomiting in patients receiving chemotherapy with irinotecan alone or combination of irinotecan plus cisplatin for unresectable gastric cancergastric cancerJPRN-UMIN000004021Division of Upper Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine80